On this page you'll find answers to commonly asked questions pertaining to Cornell IBC office functions and review of research with recombinant or synthetic nucleic acid molecules or other infectious agents during the COVID-19 Pandemic.
IBC Office Hours and Information during the COVID-19 Pandemic
A: Yes. The IBC Committee and staff are functioning remotely during regular business hours.
A: The easiest way to contact the IBC is by emailing email@example.com. You can also find contact information for specific IBC staff on our website. IBC staff are responding to both email and phone messages during regular business hours, with email being the fastest way to get in touch. Staff are also happy to arrange phone calls or Zoom meetings, as needed.
Submitting to the IBC
A: Maybe. As part of Cornell’s reduction of laboratory research (see Brief Contingency Planning guidance for Researchers March 15, 2020 research on campus should be halted with the following exceptions:
- Work that has been approved by the Cornell SARS-CoV-2 Essential Research Approval Committee (SERAC)
- Work that has been approved by the Biomedical Equipment and Testing Rapid Response (BETTR) Committee
- Work that has been deemed essential and approved as such by department chair or college dean
A: Yes if the work approved by the committees / individuals above involves use of recombinant or synthetic nucleic acid molecules or other infectious agents and is not already covered under your Memorandum of Understanding and Agreement (MUA) with the IBC you will need to amend your MUA.
The IBC is working to expedite this work considered essential under COVID-19.
A: Yes. Even if the research is paused for the time being, the PI must still submit the Annual Review or 3-year renewal to ensure that the study stays active. This will allow the research to begin immediately when appropriate and/or permitted.